Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | BRD1 | O95696 | 1/20 | 0.35 |
| ▸ | TAF1 | P21675 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253094 | 0.81 | TRIM24 (0.37) | TRIM24TRIM33BRD1TAF1BRPF1 | |
| SCHEMBL7284956 | 0.79 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1CYP2A6HRH4 | |
| SCHEMBL5266857 | 0.79 | AKR1C3 (0.38) | ALDH1A1 | |
| SCHEMBL5266851 | 0.79 | AKR1C3 (0.38) | ALDH1A1 | |
| SCHEMBL3566855 | 0.76 | MCL1 (0.38) | BRD1TAF1BRPF1ALDH1A1HRH4 | |
| SCHEMBL18000197 | 0.74 | CMA1 (0.37) | BRD1TAF1BRPF1ALDH1A1CYP2A6 | |
| SCHEMBL17673142 | 0.73 | BRD1 (0.35) | BRD1TAF1BRPF1MDM2HRH4 | |
| SCHEMBL23714603 | 0.72 | KDM4E (0.42) | TRIM24TRIM33ALDH1A1ATM | |
| SCHEMBL689437 | 0.71 | MCL1 (0.56) | ALDH1A1ATM | |
| SCHEMBL21683365 | 0.71 | GRM2 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| CN-101128424-A | Indole compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | TRIM24 3310/4885TRIM33 2692/4885BRD1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.